Comparative Analysis of Venture Capital Booms: AI vs. Dot-Com (and Biotech)

Introduction

Over the past few decades, the venture capital (VC) landscape has experienced several dramatic investment booms that reshaped entire industries. This report compares the current artificial intelligence (AI) investment boom with the late-1990s Internet “dot-com” era, and examines whether the biotech/genomics sector ever saw a similar pivot in VC direction and magnitude. We present a structured analysis with timelines, key players, funding volumes, and sectoral focuses for each era. Quantitative comparisons and tables highlight the scale of each boom, while we analyze similarities and differences in VC behavior, capital inflows, and ecosystem development.

The AI Investment Boom (2020s)

Post-2020 Acceleration: Venture funding in AI has accelerated explosively since 2020, reaching unprecedented global volumes. By 2024, nearly one-third to one-half of all VC dollars worldwide were flowing into AI startups . In 2024 alone, AI-focused companies globally raised about $100–131 billion, an increase of 52% from the prior year even as overall VC funding for non-AI startups declined . In fact, 50.8% of global VC funding by value in Q4 2024 went to AI companies – almost double the share from a year before . This marks AI as the leading sector for venture investment, with funding levels in 2024 surpassing even the peak year of the 2021 tech boom . Such rapid growth reflects a “herd mentality” in venture capital, as investors rush into the next revolution despite uncertainty about which bets will prove sustainable . Prominent AI companies have attracted mega-rounds over the past two years; for example, OpenAI (creator of ChatGPT) raised $6.6 billion in 2023 at a stunning $157 billion valuation , and Anthropic secured an up to $4 billion strategic investment from Amazon in 2023 – deals almost unheard of in earlier VC eras.

Major Investors and Mega-Projects: Unlike prior booms, the current AI surge is marked by the involvement of not just traditional VC firms but also mega-funds, corporate giants, and even government-backed initiatives. SoftBank’s Vision Fund, launched in 2017 with over $100 billion in capital, set the stage for outsized tech investments and is the world’s largest tech-focused VC fund . SoftBank, along with top Silicon Valley firms like Andreessen Horowitz (a16z) and Sequoia Capital, has aggressively shifted focus to AI—funding everything from AI chipmakers to robotics platforms. These investors are partnering in unprecedented ways; for instance, in January 2025 a joint venture called “Project Stargate” was announced as a private-sector $500 billion initiative to build next-generation AI infrastructure in the U.S. . Backed by OpenAI, SoftBank’s Masayoshi Son, Oracle’s Larry Ellison, and others, Stargate plans to construct 20 massive AI data centers, with $100 billion committed upfront and the rest over four years . This collaboration – encouraged at the highest levels of government – illustrates the colossal scale of capital being marshaled for AI. Traditional VC firms are also raising specialized funds to capture the trend, and corporate investors (like Microsoft, Amazon, Google, NVIDIA, and Oracle) are pouring billions into AI startups or partnerships. The result is a blurring of lines between venture financing and strategic corporate investment in the AI domain.

Key AI Sectors Receiving Funding: Within the AI boom, certain subsectors stand out for receiving disproportionate investment:

• Foundation Models & Generative AI: Companies developing large-scale AI models (such as language models and image generators) are prime funding magnets. Nearly one-third of all AI venture dollars in 2024 went into “foundation model” startups . These include firms like OpenAI, Anthropic, Cohere, and new entrants like Mistral AI, all of which raised some of the year’s largest rounds . Such companies often command valuations in the tens of billions despite limited revenue, as VCs bet on their platforms becoming fundamental infrastructure.
• AI Chips and Infrastructure: The race to build specialized hardware for AI has led to massive VC bets on semiconductor startups. Companies like SambaNova Systems and Horizon Robotics each raised over $1 billion in funding to develop AI accelerators , with SambaNova’s $676 million Series D valuing it above $5 billion . Likewise, U.K.-based Graphcore has garnered $710 million to date . Investors (including SoftBank’s Vision Fund) recognize that challenging incumbents like NVIDIA requires enormous capital . As a result, the AI hardware sector has seen multiple “unicorn” startups (valuations > $1B) in a short span.
• Robotics and Autonomous Systems: Venture capital has also heavily funded AI-driven robotics and autonomous vehicles. In the 2010s, self-driving car ventures alone raised tens of billions (the autonomous vehicles sector saw $56.6B of funding over the decade, peaking at $12.8B in 2021) . Companies like Cruise (backed by SoftBank with $2.25B in 2018) and others exemplified this wave. More broadly, AI-powered robotics startups – from warehouse automation to humanoid robots – attract large rounds as VCs anticipate an automation revolution. By 2024, robotics was again listed among the leading AI investment areas .
• Applied AI in Various Industries: The remaining two-thirds of recent AI funding has flowed into applying AI across sectors . Notable areas include healthcare AI (e.g. drug discovery platforms), fintech and professional services automation, cybersecurity AI, and even defense (military AI projects). Each of these domains is seeing record venture investments as AI technology matures. For example, startups offering AI-enabled drug design and diagnostics surged after 2020, and by 2024 healthcare was among the top sectors for AI VC deals .

Timeline – Key Moments in the AI Boom:

• 2017–2019: Early groundwork as SoftBank’s $100B Vision Fund launches, investing heavily in AI and robotics companies . Global AI startup funding grows steadily (tens of billions per year).
• 2020: COVID-19 pandemic boosts digital adoption; interest in AI grows. GPT-3 is released, demonstrating the power of large language models.
• 2021: Record VC year overall; AI investments estimated around $92–93B globally . Multiple AI chip startups achieve unicorn status.
• 2022: OpenAI’s ChatGPT launch (Nov 2022) triggers mainstream awareness. AI investment enters a frenzy as companies across industries seek to integrate AI .
• 2023: Generative AI hype peaks – startups like OpenAI, Anthropic, Inflection, and others raise multi-billion rounds or strategic investments. Global VC funding into AI hits ~$55B in 2023 . Tech giants (Microsoft, Google, Amazon) make landmark investments (e.g. Microsoft’s multi-year ~$10B OpenAI deal).
• 2024: “Breakout year for AI.” AI funding doubles year-over-year to over $100B , even as broader VC funding is flat. Q4 2024 sees half of all venture capital go to AI . Mega-project Stargate ($500B) is announced, aiming to cement AI infrastructure leadership in the U.S. .
• 2025: Continued momentum with large partnership deals (the Stargate consortium begins building data centers ). In Q1 2025, a single $40B AI-related transaction helped push VC funding to its highest post-2022 quarter , signaling that enthusiasm remains very strong.

The Dot-Com Era Internet Boom (1995–2002)

Surge of Internet VC Investment: The dot-com boom of the late 1990s was characterized by a rapid influx of venture capital into Internet startups, rivaling the intensity of today’s AI frenzy. Annual VC funding in the U.S. skyrocketed from around $5–6 billion in 1995 to well over $30 billion by 2000, a >5-fold increase . (One analysis notes VC funding climbed from $3B in 1995 to $33B in 2000 , illustrating the order-of-magnitude growth.) By the peak of 1999–2000, venture capital had largely redirected towards “dot-com” ventures: in 1999, about 39% of all U.S. VC investments went into Internet-related companies . This reflected a herd mentality similar to today’s—VCs feared missing out on “the next big thing” as the internet’s potential to revolutionize business became apparent . The surge was fed by a frenzy of IPOs and media hype. In 1999, a record 457 IPOs were held (most of them Internet companies), and another 91 dot-com IPOs launched in just the first quarter of 2000 . Capital was cheap and plentiful: “record amounts of capital” flowed into tech, and valuations for dot-com startups soared despite many having no profits (or even revenues) .

Key Players and Investment Focus: A hallmark of the dot-com era was the prominent role of Silicon Valley VC firms that became kingmakers of the Internet age. Sequoia Capital and Kleiner Perkins Caufield & Byers (KPCB) led early investments in companies like Google and Amazon, respectively, while firms such as Benchmark Capital, Accel Partners, and others backed dozens of e-commerce and web startups. These VCs raised some of the largest funds of the time to pour into internet deals (Sequoia, for example, raised three funds in 1999–2000 to capitalize on the boom ). The sectors funded during this period centered on the burgeoning World Wide Web:

• Online Retail and E-Commerce: Startups like Amazon (online books and beyond), eBay (online auctions), Webvan (online grocery), and Pets.com exemplified the rush to bring traditional commerce onto the internet. E-commerce attracted billions in VC and several high-profile IPOs (Amazon in 1997, eBay in 1998, etc.).
• Search, Portals, and Web Services: Search engines and web portals were a hot area – Yahoo! (founded 1995, IPO 1996) and later Google (founded 1998, VC funding from Sequoia & KPCB in 1999) became star investments. Companies offering web hosting, email services, and home pages (GeoCities, Lycos, etc.) also drew funding as gateways to the Internet.
• Telecom and Infrastructure: To support the internet boom, a parallel investment surge went into telecommunications and network infrastructure. Venture-backed firms laid fiber optic networks and built hardware for the expanding internet traffic. (This included telecom startups, data center hosts, and “B2B” internet infrastructure companies.) Although less visible to consumers, these were crucial in enabling the dot-com expansion.
• Enterprise Software and IT: The late ’90s also saw rising investment in software companies leveraging the internet or servicing the many new online businesses (from web development tools to enterprise resource planning software).

Scale and Pace of Redirection: Venture capitalists in the late ’90s rapidly reallocated their focus to chase internet deals. The average deal sizes grew and competition to fund “.com” companies intensified. By 1999, an internet startup’s average VC round was over $9 million – larger than traditional tech deals at the time . Notably, by 1999 most IPOs were dot-coms, and VC funding records were being smashed each quarter. In the first half of 1999, for example, a single subsector (business-service internet companies) attracted $2.18B – exceeding what that category had received in all prior years combined . VC investment overall hit its all-time high in 2000 (the MoneyTree report would later note 2000 as a wild peak in both deals and dollars) . However, this redirection happened over just a few years – a faster and more frenzied ascent than seen in many other eras. In summary, venture capital “skyrocketed” into internet startups, chasing first-mover advantages and market share over profits .

Timeline – Key Moments in the Dot-Com VC Boom:

• 1994–1995: The World Wide Web goes mainstream with user-friendly browsers (Netscape IPOs in 1995 with a 165% first-day pop). VC interest in internet startups begins; annual VC investment in 1995 is ~$5–6B .
• 1996–1998: Accelerating investment. Amazon (’96) and eBay (’97) receive VC and go public, validating online business models. By 1998, internet IPOs and private valuations are climbing quickly; in Q4 1998, VC funding to Internet companies hit $1.6B – an “extraordinary” volume at the time .
• 1999: Internet mania peaks. Venture funds pour money into any startup with “.com” in its name. 39% of all U.S. VC dollars in 1999 went to dot-coms . Over 280 internet companies IPO during the year . VC deal pace and valuations reach record highs; many companies raise multiple rounds within months.
• March 2000: The NASDAQ stock index peaks (March 10, 2000) and then starts to decline, marking the beginning of the end for the bubble. VC investments in 2000 are still extremely high (estimated $36–$40B+ in U.S. VC deployed in 2000, making it the biggest year ever) . Late-stage dot-coms raise huge private rounds in early 2000, but cracks are showing as some high-profile startups struggle.
• 2001–2002: Dot-Com crash. The bubble bursts—by end of 2001, most dot-com startups have either gone bust or lost the vast majority of their market value . VC investment plummets. In Q4 2001, VC firms invested just $7.1B, barely one-third of the $20.9B invested in Q4 2000 . IPOs dry up (virtually no internet IPOs in 2001). The investor euphoria turns to caution, and many VCs refocus on fundamentals. 2001’s total VC funding (~$36.5B) ends up still being the third-largest year on record due to the strong first half, but the trend sharply reverses . The dot-com era effectively ends with a painful correction, though it leaves behind enduring giants (Amazon, eBay, Google, etc.) and the backbone of the Internet economy.

Biotech/Genomics Venture Cycles (A Conditional Third Surge)

Boom-and-Bust Cycles in Biotech: The life sciences sector has experienced its own investment cycles, though generally more muted in VC impact than the dot-com or AI booms. One notable surge was the early-2000s genomics boom, which coincided with the completion of the Human Genome Project (2003) and breakthroughs in biotechnology. Around 1999–2000, excitement about genomics and biotech advances led to a spike in funding and public offerings for biotech startups (sometimes dubbed the “genomics bubble”). Venture investment into biotech companies climbed in the late ’90s, only to crash alongside the dot-com bust. Many biotech startups with genomics focus were funded on the premise of revolutionizing medicine, but most had no revenues; when the market corrected, biotech VC funding pulled back sharply. Indeed, the 2000 genomics bubble burst contributed to a decade-long slump (2001–2011) in biotech venture funding . During that slow period, only about $4 billion per year on average was invested into biotech startups (globally) . This was a small fraction of total VC and reflected investor caution toward biotech risk in the 2000s.

Biotech Resurgence in the 2010s: A more sustained biotech boom unfolded from the early 2010s through 2021, driven by new scientific breakthroughs and a favorable funding environment. After years of stagnation, the biotech VC scene reignited around 2013, helped by advances like CRISPR gene editing (2012), successful new drug modalities (e.g. immuno-oncology therapies around 2013–2014), and supportive regulatory changes. The IPO window reopened for biotech in 2013, signaling renewed investor appetite. From 2013 onward, venture funding in life sciences climbed rapidly. By the late 2010s, generalist tech investors and large funds began to join traditional biotech VCs in funding healthcare startups. This boom accelerated dramatically through 2020–2021: in 2021, an all-time high of $37 billion was invested in biotech startups, roughly 9× the annual investment a decade prior . Fueling this was a combination of factors: mRNA vaccine success (e.g. Moderna, a biotech startup incubated by Flagship Ventures, hit commercialization with COVID-19 vaccines), a low-interest-rate environment that made capital plentiful, and a surge of specialized biotech IPOs and SPACs. By 2021, biotech companies were raising mega-rounds reminiscent of tech startups, and some cities like Boston saw biotech funding reach record levels.

Directional Shifts and Major Players: The influx of capital into biotech was notable, although it never dominated VC to the extent of internet or AI booms. At peak, life sciences might account for roughly 20% of VC funding in the U.S., compared to one-third or more for AI today. However, the directionality shift was clear – after 2013, investors became more willing to fund early-stage biotechs (even those years from revenue) due to promising science. Top specialist VC firms like Flagship Pioneering, ARCH Venture Partners, Third Rock, and Orbimed led many big biotech deals, while multi-sector funds (a16z, Sequoia, SoftBank’s Vision Fund 2, etc.) also made biotech bets during the peak. For example, SoftBank’s Vision Fund invested in gene-sequencing company Guardant Health and others, and a16z launched bio-focused funds in the late 2010s. Big pharma companies contributed via venture arms and collaboration deals, injecting capital into biotech startups (analogous to how big tech aids AI startups). Some notable investments/projects of this boom included: the founding of Moderna (Flagship incubated it with early tens of millions; IPO’d 2018 and soared to >$100B valuation in 2021), the rapid funding and IPOs of CRISPR gene-editing startups like Editas and Intellia (mid-2010s), and the rise of CAR-T cancer therapy companies (Juno, Kite – both VC-backed and acquired for ~$10B by 2017–2018). Venture financing for biotech hit then-record highs mid-2015 as well, with $2.3B in VC poured into biotech in just Q2 2015 (a 32% year-over-year jump) – prompting observers even then to ask if it was a bubble. After a brief correction around 2016, the sector took off again to reach the 2020–2021 apex.

Timeline – Highlights of Biotech VC Trends:

• 1990s: Steady but modest biotech VC activity, focused on early biotech pioneers (Amgen, Genentech) and new genomics startups. The 1999–2000 peak sees a flurry of biotech IPOs alongside tech IPOs; e.g. Celera Genomics (genome sequencing company) soars then crashes.
• 2003: Human Genome Project completed, but biotech funding is in trough. From 2003 to 2011, roughly $4B/year invested in biotechs globally – a low level indicating VC skepticism post-bubble. Few biotech IPOs occur (2007–09 saw virtually none ).
• 2013: Start of the biotech boom. Scientific wins (e.g. Gilead’s cure for hepatitis C, first gene therapy approvals, CRISPR’s discovery) restore optimism. The FDA introduces faster approval pathways (Breakthrough Therapy designation in 2012) which boosts valuations of drug developers. Biotech IPOs resume in 2013 with strong investor reception.
• 2015: Venture funding in biotech hits then-record levels (over $2B in a quarter ). High-profile biotech startups raise large rounds, and NASDAQ biotech index hits a peak in mid-2015. Concerns of a bubble arise but a major crash is averted; instead a mild correction occurs 2016–2017.
• 2018–2019: Biotech VC rises again. New modalities (gene therapy, gene editing, precision medicine) attract capital. Pharma companies are aggressive in acquiring successful startups, encouraging more VC investment. SoftBank launches a $5B+ second Vision Fund which allocates to some biotech/healthtech companies, showing crossover interest.
• 2020–2021: Record biotech funding. The pandemic highlights biotech’s importance – vaccine developers and diagnostics startups get funding boosts. Globally, biotech and pharma startups raise over $23B in 2020 (60% higher than 2019) , and even more in 2021. IPOs of startups like Moderna and others mint new giants. VC funding for biotech hits ~$37B in 2021 , an all-time high.
• 2022–2023: Post-boom cooling. As interest rates rise and some hype cools, biotech VC funding retreats from the 2021 high. Nonetheless, by 2024 the biotech industry remains robust, with quarterly global funding still on the order of ~$6–8B (higher than the pre-2013 era). Biotech remains an important, if cyclical, pillar of venture investment rather than a short-lived fad.

Note: While the biotech surges significantly impacted the life sciences ecosystem and produced transformative medical innovations, they did not seize the majority of global VC capital in the way the dot-com and AI booms did. Biotech’s share of VC peaked in the 15–20% range, whereas Internet and AI booms saw much larger portions of capital redirected into those fields . Thus, biotech is a conditional comparison – a major boom by its own historical standard, though more sector-specific and modest relative to the broader venture market.

Comparative Analysis of VC Booms

To conclude, we compare the AI boom (2020s), the dot-com boom (late 1990s), and the biotech surges on key dimensions:

• Magnitude of Capital Inflows: In absolute terms, the current AI boom is drawing the largest VC investment totals. Annual global VC funding for AI reached ~$100B+ by 2024 , whereas at the height of the dot-com bubble around 1999–2000, annual VC investment (all sectors) in the U.S. was on the order of ~$36–$40B (with perhaps ~$15–$20B of that in Internet deals in 1999 ). Adjusting for inflation and global capital growth, the AI boom’s scale is unprecedented, enabled by larger fund sizes and corporate co-investors. The dot-com era was also enormous for its time – venture investment grew ~10x from the mid-90s to 2000 – but the VC industry itself was smaller then. Biotech’s boom, while record-setting for that sector ($37B in 2021 ), is smaller than the others in sheer dollars. One way to compare is by share: dot-com companies took nearly 40% of U.S. VC at peak ; AI startups took ~33% of U.S. VC by 2024 and over 50% globally in late 2024 ; biotech at peak was perhaps 20% or less. Thus, AI and dot-com booms represent more dramatic redirections of the venture ecosystem.
• Pace and Duration of Boom: The dot-com boom was shorter and more extreme – roughly 5 years from nascent to peak, followed by a crash. Investment spiked sharply in 1999–2000 and then collapsed by 2001 . The AI boom has ramped up quickly (particularly post-2022), but it is still ongoing in 2025; it remains to be seen if it sustains or also faces a sharp correction. The AI cycle has been less tied to public stock IPOs so far (more late-stage private funding and strategic deals), which could mean a different trajectory. Biotech’s cycle in the 2010s was more gradual – nearly a decade-long boom with ups and downs, partly buffered by the fact that biotech breakthroughs take time and the sector’s fortunes often move with scientific/regulatory cycles rather than pure market fashion.
• Investor Behavior – Hype vs. Fundamentals: All three eras exhibited classic “FOMO” (fear of missing out) behavior among investors. As economist Bill Janeway noted, when a technological innovation has broad potential, VCs place many bets despite uncertainty, in hopes of finding the big winners . During the dot-com rush, many investors abandoned cautious due diligence “for fear of not being able to cash in on the growing use of the Internet” . This led to speculative excesses – e.g. startups with no viable business plans raising millions, simply because they had an internet angle . In the AI boom, we similarly see very high valuations based on future promise (e.g. a pre-revenue AI lab valued over $100B). Investors in both eras justified this by the potentially winner-takes-all nature of platform technologies (network effects for the internet; scale advantages in AI models). Biotech investment, in contrast, has always been tempered by the realities of scientific risk – though the 2020–21 frenzy did introduce some “tech-like” excess into biotech (many startups IPO’d at the preclinical stage, a fact unheard of a decade prior). Overall, herd mentality and rapid inflows are common threads, but the severity of the speculative bubble was greatest in dot-com (which famously burst), whereas the AI boom is still in a phase of enthusiastic expansion, and biotech’s cycle was buoyed by tangible scientific progress (vaccines, cancer therapies) that provided more fundamental underpinning for valuations.
• Major Players and Ecosystem Development: Each boom saw a different mix of key players:
  • Dot-Com: Dominated by venture capital firms and public market investors (IPO buyers). Major VC firms on Sand Hill Road became synonymous with tech entrepreneurship. The ecosystem developed internet infrastructure and consumer online services; even after the crash, the surviving companies (Amazon, Google, Cisco, etc.) and the fiber-optic networks laid in that era formed the bedrock of today’s digital economy.
  • AI: Characterized by a convergence of VC, Big Tech, and government. Large tech companies (e.g. Microsoft, Google, Amazon, NVIDIA) are co-driving the boom by investing directly in startups and providing resources (cloud credits, chip expertise). Gigantic funds like SoftBank’s Vision Fund and nation-backed funds (e.g. Middle East sovereign wealth in Vision Fund) contribute to an unprecedented capital pool. Collaborative projects like the $500B Stargate initiative show government interest in staying ahead in AI infrastructure . The AI ecosystem thus is developing with heavy involvement of incumbents: new AI startups often partner with or get acquired by big players (Microsoft/OpenAI, Google/Anthropic, etc.), and a huge amount of capital is going into infrastructure (data centers, chips) which lays a foundation for long-term AI capabilities. This top-heavy support could mean the AI boom, even if individual startups falter, leaves behind a lasting infrastructure and technology layer (much like dot-com built the internet’s backbone).
  • Biotech: Led by a combination of specialist VCs and pharmaceutical companies (via partnerships and venture arms). The biotech booms prompted the growth of bio-incubators and startup studios (Flagship’s model created multiple companies like Moderna). Big pharma often stepped in to acquire successful ventures (providing exits for VCs). The ecosystem impact of the biotech boom is evident in the number of new therapies and technologies (mRNA vaccines, gene therapies, etc.) that emerged from VC-backed companies. Biotech booms also strengthened hubs like Boston and San Francisco as biotech innovation centers. However, biotech’s venture ecosystem remains somewhat siloed from general tech – it did not cause a wholesale shift of all VC firms toward biotech in the way that “every VC is now an AI investor” in 2023.
• Outcomes and Corrections: The dot-com boom ended in a dramatic bust, wiping out trillions in market value. Venture portfolios suffered huge losses circa 2001–2002, but importantly, the internet did not disappear – the groundwork laid by those investments later enabled Web 2.0 and the modern tech giants. The AI boom is ongoing, but some skeptics caution about a possible “AI bubble.” If a correction comes, it may not mirror the dot-com collapse because many AI innovations are being integrated into existing products (providing some revenue streams for big tech) and the largest funding recipients have substantial backing. Nonetheless, the risk of over-capacity (too many similar AI startups and overbuilt AI infrastructure) exists, which could lead to a shakeout. For now, VC activity in AI remains near its peak. The biotech boom of the 2010s saw a partial correction after 2021: rising interest rates and a tougher IPO market in 2022 led to a pullback, and many cash-hungry biotechs faced funding challenges (the sector is known for boom-bust cycles tied to broader economic conditions). However, biotech did not “crater” as brutally as dot-com; instead, it saw a measured decline and then stabilization, with investors becoming more selective (as of 2023–2024, biotech VC funding is down from 2021 but still healthy by historical standards) .

Similarities: In both the AI and dot-com epochs, venture capital behavior showed strong parallels – rapid inflow of funds chasing transformative tech, a high concentration of capital in one theme, and industry rhetoric about “a new paradigm” that justifies unconventional valuations. Both eras created iconic companies and significantly advanced their respective technologies. Biotech’s pattern, while driven by scientific milestones, also followed the core idea that major innovations attract major capital (and that capital can surge ahead of actual products, banking on future potential). All three booms underscore how VC is often cyclical and sentiment-driven, oscillating between exuberance and retrenchment.

Differences: The role of the public markets differed – dot-com startups often IPO’d early (many failed as public companies), whereas AI startups in the 2020s have stayed private longer or partnered with incumbents, with IPOs still rare in this space as of 2025. Additionally, the source of funds has expanded: 1990s VC came mostly from limited partners in VC funds, but 2020s AI funding includes corporate balance sheets and government-supported funds at a scale not seen before. In biotech, the timescales of value creation are longer (drug development can take a decade), so the boom’s payoff is slower and tied to clinical success rather than network effects or user growth as in internet/AI. Finally, societal impact differs: the dot-com boom democratized information and commerce, the AI boom is automating cognitive tasks across society, and biotech’s boom targets human health – each has a distinct legacy beyond just investor returns.

Conclusion

The current AI venture boom is rivaling – and in some ways surpassing – the dot-com era in its scale and fervor. Both periods saw venture capital redirect on a global level toward a revolutionary technology, backed by a mix of optimism and fear of missing out. If history is a guide, some of today’s AI startups will become the foundational companies of the future (just as Google and Amazon emerged from the dot-com rubble), while others will fade after the hype. Biotech’s venture surges serve as a reminder that not every boom busts completely; sometimes a sector can sustain higher investment levels if underpinned by real progress, albeit with volatility.

In summary, venture capital booms tend to follow a pattern: a compelling innovation triggers a massive inflow of funds, investment volumes multiply within a few years (e.g. 5× or more growth) , a handful of firms and sectors absorb most of the money , and the ecosystem is permanently changed – for better or worse. The late 1990s changed how we use the Internet, the biotech boom is changing how we treat disease, and today’s AI boom is poised to redefine how intelligence and automation are woven into the economy. Venture capitalists, old and new, will continue to learn from these cycles: balancing bold bets on the future against the lessons of past excesses. As of 2025, the AI boom marches on, making this a pivotal moment that will be studied alongside the dot-com and biotech eras as a defining chapter in venture capital history.

References: The information above is drawn from a range of sources, including investment analyses, historical data, and news reports. Key data points on funding volumes and investor behavior were sourced from PitchBook and Crunchbase analytics , contemporary news (Reuters, Forbes) on major initiatives like the $500B AI infrastructure project , historical accounts of the dot-com era , and industry reports on biotech funding trends , among others. These sources provide a quantitative backbone and context for the qualitative assessment of each boom’s drivers and outcomes. Each citation in the text corresponds to specific supporting details from these sources.